Holen Sie sich die Stockscreener-App
0.00
100.00%
-10.14
Handel nachbörslich:
10.14
10.14
+
Translational Development Acquisition Corp Aktie (TDACU) Neueste Nachrichten
Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development - Yahoo Finance
Stock market today: Wall Street finishes a winning week just shy of a record - 69News WFMZ-TV
Translational Development Acquisition Corp. Announces that the Separate Trading of its Class A Ordinary Shares and Warrants has Commenced - Yahoo Finance
Quaker Oats recalls 10,000 boxes of Pearl Milling Company pancake mix for milk allergy risk - 69News WFMZ-TV
Major SPAC Update: TDACU Splits Units into Separate Shares & Warrants Trading - StockTitan
Trident Acquisitions stock hits 52-week high of $10.08 - MSN
Trident Acquisitions stock hits 52-week high of $10.08 By Investing.com - Investing.com South Africa
ImmuPharma (LON:IMM) Stock Price Up 9.3% – Here’s Why - Defense World
Rockhopper Exploration (LON:RKH) Shares Down 8% – Here’s What Happened - Defense World
Health In Tech, Inc.’s (NASDAQ:HIT) Quiet Period To End on February 3rd - Defense World
Translational Development Acquisition Corp.’s Quiet Period Set To Expire on February 3rd (NASDAQ:TDACU) - Defense World
Research Analysts Issue Forecasts for BHC FY2025 Earnings - Defense World
TDACU stock touches 52-week low at $10 amid market challenges - Investing.com
Special Purpose Acquisition Company (SPAC) News and Analysis - SPACInsider
TDACU stock touches 52-week low at $10.01 amid market shifts - Investing.com Canada
NextCure Initiates Phase 1 Study for B7-H4 ADC Therapy to Treat Multiple Cancers_ - Defense World
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Yearend 2024 SPAC Market Update & Outlook - Business Wire
Trident Acquisitions stock hits 52-week high at $10.04 - Investing.com India
Trident Acquisitions stock hits 52-week high at $10.04 By Investing.com - Investing.com UK
Translational Development Acquisition Corp. Announces Closing of $172.5 Million Initial Public Offering, Including Full Exercise of Underwriter's Over-Allotment Option - Finansavisen
Translational Development (TDACU) Raises $172.5M in Successful Nasdaq IPO, Begins Trading - StockTitan
Translational Development Acquisition Corp. Announces the Pricing of $150,000,000 Initial Public Offering - The Eastern Progress Online
Translational Development Acquisition Corp Launches $150M IPO on Nasdaq, Units to Trade as TDACU - StockTitan
Translational Development Acquisition Corp. (TDACU) Prices $150M IPO - SPACInsider
What’s next for the man charged with killing UnitedHealthcare’s CEO? - 69News WFMZ-TV
Italy's privacy watchdog fines OpenAI for ChatGPT's violations in collecting users personal data - 69News WFMZ-TV
For airports, background music no longer is an afterthought - 69News WFMZ-TV
The Fed expects to cut rates more slowly in 2025. What that could mean for mortgages, debt and more - 69News WFMZ-TV
Valink Therapeutics Appoints Biopharmaceutical Veteran Martin D. Williams as Chair of the Board of Directors and Names Scientific Advisory Board - Business Wire
(PDF) Translational Science: A Road Map for the Science of Reading - ResearchGate
Mestag Therapeutics Expands Leadership Team and Appoints Head of Development and General Counsel - GlobeNewswire
Deal Watch: Dealmakers Brace for Impact of Presidential Election - Law.com
IPO NewsUS IPO Weekly Recap: Sizable tech and biotech IPOs are joined by a flurry of small names - Renaissance Capital
(PDF) Measuring Translation Competence Acquisition - ResearchGate
NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines - Business Wire
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential - Ipsen
Iron controls the development of airway hyperreactivity by regulating ILC2 metabolism and effector function - Science
Congruence Therapeutics Appoints Experienced Drug Developer Michael D. Harvey, Ph.D. as Chief Development Officer - PR Newswire
Novartis Extends Its Reach in Radiopharmaceuticals With $1B Mariana Oncology Acquisition - MedCity News
Rounding up the pharma firms investing the most in 2023 - Drug Discovery & Development
NanoString Technologies to Be Acquired by Bruker Corporation - Business Wire
Initial Public Offering (IPO) News Live Feed - StockTitan
Novo Nordisk Expands Boston Area Research and Early Development - Genetic Engineering & Biotechnology News
Merck to Acquire Caraway Therapeutics, Inc. - Business Wire
Organoids Evolve from Academic Marvel to Industrial Tool - Genetic Engineering & Biotechnology News
Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases - PR Newswire
Locks on Translation Initiation May Restrain Cancer - Genetic Engineering & Biotechnology News
Offerings News Live Feed - StockTitan
Odyssey Therapeutics Appoints Jeremy Sokolove, MD as Chief Medical Officer - BioSpace
NIH launches new initiative: Tackling Acquisition of Language in Kids (TALK) - NIDCD
NextRNA Therapeutics Strengthens Board of Directors with Appointment of Lori Friedman, PhD - Business Wire
FirstEnergy issues earnings report - 69News WFMZ-TV
Bollman Hat Company merges with GJ Littlewood & Son - 69News WFMZ-TV
ODDITY Invests $100M to Bring Pharma’s AI Based Molecule Discovery Technology to Beauty and Wellness. - Business Wire
Zura Bio Announces Appointment of Chief Scientific Officer - Business Wire
Cube Psytech Signs Letter of Intent to Acquire Translational Life Sciences and Announces Private Placement - ACCESS Newswire
BMS Collaboration Paying Off for Exscientia - Genetic Engineering & Biotechnology News
Developing a metabolic clearance rate framework as a translational analysis approach for hyperpolarized - Nature.com
Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer - Business Wire
0.95%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):